Exploring the Use of Orca-T for Patients With Acute and Chronic GVHD

Video

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

Mehrdad Abedi, MD, a professor of cancer, hematology/oncology, and internal medicine in the Department of Internal Medicine, Division of Hematology and Oncology at the UC Davis Comprehensive Cancer Center, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease (GVHD).

Orca Bio approached UC Davis a few years ago to start collaborative research with the Good Manufacturing Practice facility and produce these products. Each graft of the Orca-T product has stem cells and immune cells in it. The stem cells are needed to maintain the graft and allow the product to stay in the patient for a long time, according to Abedi. The immune cells cause graft-vs-leukemia effects, which is what they want.

Abedi says it is clear that there is a population of T cells called T-regulatory cells that can prevent GVHD as seen in work from multiple investigators. There are other populations, such as the naïve T cells or conventional T cells, that can cause GVHD. A smaller number of those cell may be helpful; they can cause graft-vs-leukemia, but not GVHD.

The graft is designed so that the investigators can give stem cells, but they remove a lot of conventional T cells that can cause GVHD. The graft provides a small amount of conventional T cells that can cause graft-vs-leukemia effects, as well as the regulatory T cells that can prevent GVHD, Abedi explains.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content